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ABSTRACT 18 
Background. The Cancer Drugs Fund (CDF) was introduced to provide cancer patients in England 19 
with access to drugs not appraised or approved by the National Institute for health and Care 20 
Excellence (NICE).  We studied press coverage of the CDF in UK newspapers in 2010-15. 21 
Methods.  Newspaper stories in the Factiva database were sought, and details copied to a spreadsheet.  22 
They were categorised by whether they were supportive or critical of the CDF, which drugs they 23 
mentioned and for which cancers. 24 
Results.  Press coverage was mainly very positive, arguing for the CDF’s extension to Scotland and 25 
Wales, and a bigger budget, but neglecting the lack of patient benefit and the severe side effects that 26 
sometimes occurred.  Leading this support was the Daily Mail, whose influence (measured by the 27 
product of number of stories and the paper’s circulation) was almost greater than that of the other 28 
newspapers combined. 29 
Conclusions.  Although there was some  critical analysis of the CDF, ,our analysis shows that most 30 
press coverage was largely positive, and unrepresentative in comparison with the lack of overall 31 
benefits to patients and society.  It is likely that it contributed to the CDF’s continuation despite 32 
mounting evidence of its ineffectiveness. 33 
  34 
 2 
KEY MESSAGES:  35 
 36 
• The Daily Mail, the Daily Telegraph and The Times published the greatest volume of 37 
news stories regarding the CDF 38 
 39 
• The Daily Mail had the greatest “influence” of the newspapers, based on the product 40 
of number of stories and circulation 41 
 42 
• The majority of news stories regarding the CDF were positive calling for an increase 43 
in coverage to the devolved UK territories and for greater funding. 44 
 45 
• Of the news stories mentioning specific drugs, abiraterone, bevacizumab and 46 
trastuzumab were the most frequently cited.  47 
 48 
• CDF stories related to particular tumour types were not in keeping with their relative 49 
burden as measured by DALYs, with breast cancer over-represented in news articles 50 
compared to lung cancer which was under-represented. 51 
 52 
BACKGROUND 53 
The Cancer Drugs Fund was established by the UK coalition government in 2010 to provide 54 
access to drugs not available through the English NHS. Some of the drugs available through 55 
the fund awaited formal assessment by NICE (National Institute for Health and Care 56 
Excellence), whilst others had been previously appraised but not recommended for routine 57 
funding by the NHS. In 2011, the Cancer Drugs Fund had an annual budget of £200m. The 58 
lifespan of the fund was extended over time, along with its budget (increasing to £340 million 59 
in 2015-16). However, even though two re-prioritisation exercises were undertaken, the final 60 
outturn position for 2015/16 was £466m - an overspend of £126m (37%).Close to £1.4 billion 61 
in total has been spent on cancer drugs through this fund.1 2 The CDF has subsequently been 62 
reconfigured and is now under the control of NICE.2 63 
An analysis of the CDF between 2010 and 2015 has shown that it delivered poor value for tax 64 
payers and for patients, with only 38% of approved drugs achieving a statistically significant 65 
improvement in overall survival and only 18% meeting thresholds for a clinically meaningful 66 
benefit according to value scales developed by professional bodies.3 Put simply, many of 67 
these drugs did not offer any benefit with respect to prolongation of life or improvement in 68 
quality of life, and access was achieved at considerable financial and opportunity cost with 69 
little evidence that patients on the fund benefited.   70 
 3 
The CDF was created following intense public and political pressure to provide access no 71 
matter what the cost or the evidence for their benefit.  This was a debate played out in the 72 
media, which resulted in a changing role for NICE and the creation of the CDF.4 In this 73 
analysis, we have sought to investigate the volume and representativeness of media reporting 74 
about the CDF between 2010-2015, specifically highlighting key differences between media 75 
outlets in their support for, or opposition to, the fund, and the likely impact on public and 76 
political perception given the “impact” or “influence” of particular newspapers. We also 77 
assessed the drugs most frequently cited in newspaper reports to see whether any 78 
concordance existed with actual prescribing patterns.  79 
METHODS 80 
Inclusion criteria 81 
The full-text database Factiva © Dow Jones was searched between 1 January 2010 and 31 82 
December 2015 for stories in the nine national newspapers that have a circulation across the 83 
UK (see Table 1) that contained the phrase "cancer drugs fund". The stories were retained for 84 
analysis (by PR and GL) only if the CDF was the main focus of the story.   85 
The full text of each story meeting the inclusion criteria was analysed thematically and the 86 
following information collected: the story's date, the newspaper, the headline and the 87 
synopsis, as well as the word count.  Details of the journalist’s name and position (if given), 88 
the names of the drugs and the cancer site for which they were intended to be used, were also 89 
recorded. Higher thematic codes were derived as either positive (supporting the CDF), 90 
neutral, or negative (critical of it). In conjunction with the higher “sentiment” themes,  91 
subject area themes were also coded. The codes were modified iteratively7during the analysis 92 
of the stories.  The codings were developed by PR and RS, and if there was disagreement, 93 
there was discussion with AA and GL to resolve the issue.  For example, positive newspaper 94 
stories were identified that advocated a widening of the geographical coverage of the CDF 95 
beyond England to the other devolved territories (e.g. Wales).  Similarly, negative stories 96 
about the CDF were identified that focused on the effect that the CDF had in re-directing 97 
money away from other areas of the NHS.  Further analyses sought to measure the 98 
comparative “influence” of each newspaper’s reporting of the CDF with a  metric specifically 99 
developed for this evaluation.  This was determined for each of the nine newspapers as the 100 
product of its circulation (obtained from the Audit Bureau of Circulation, 101 
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https://www.abc.org.uk/) and the number of stories. Influence was calculated with and 102 
without the inclusion of the length of the article (word count). 103 
In addition, we analysed whether there was any concordance between the types of cancer 104 
mentioned in the newspaper reports and the burden of disease from each tumour type in the 105 
UK in 2010 measured in Disability Adjusted Life Years (DALYs).5  This indicator sums the 106 
reduction in life expectancy (e.g. premature mortality compared with Japan, with the highest 107 
life expectancy) and the number of years spent living at less than full health (disability).  The 108 
DALY gives a better measure of disease burden from different cancers by including 109 
morbidity and mortality.  .  The analysis is designed to assess whether newspaper coverage of 110 
particular tumour types correlates with their health burden on the population. 111 
RESULTS 112 
Outputs of stories in the different newspapers 113 
Out of a total of 1692 stories that mentioned the Cancer Drugs Fund, we excluded 1310 that 114 
were about other topics and only mentioned the CDF peripherally.  In the 382 media stories 115 
retained for analysis that discussed the CDF in some detail, 44 different cancer drugs were 116 
identified, 16 different cancer sites were mentioned and 142 different journalists were named 117 
as authors.  Following the launch of the CDF in 2010, coverage (the number of published 118 
stories) was fairly steady from 2010 to 2012 and thenincreased from 2012 to 2015 (Figure 1).  119 
The Daily Mail had the greatest calculated influence (based on frequency of stories and 120 
newspapers circulation (Table 1).  Including article length, which quantified whether an 121 
article was a minor item or feature story, made no difference to the rank of CDF reported 122 
‘influence’, therefore the simpler, frequency of story x circulation calculation is used.  The 123 
table makes clear that the Daily Mail had almost as much influence as the other eight daily 124 
papers together, and that this was more than three times the influence of any other paper 125 
according to our metric.  126 
The tone of the stories and the weight of opinion 127 
Eleven broad themes were identified.   The codes and their relative frequency are listed in 128 
Table 2.  Seven of the codes related to positive reporting of the cancer drugs fund (in green), 129 
three related to negative reporting (in red) and one was neutral (black). 130 
Figure 2 demonstrates the editorial balance of stories about the CDF (positive, neutral and 131 
negative) for each individual newspaper. For four newspapers the majority of their stories 132 
were consistently positive regarding the CDF (Daily Mail, The Sun, Daily Express and Daily 133 
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Mirror), one was more negative (Financial Times) and the four remaining newspapers 134 
showed a mixed picture of positive, negative and neutral tones in their stories. The 135 
combination of this chart, Table 2 and the influence scores shown in Table 1, illustrates the 136 
significant positive reportage of the CDF overall, particularly in the Daily Mail.   137 
The dominant narrative was one of praise for the CDF in providing access to drugs that were 138 
needed by cancer patients, but had previously been denied.  Where the narrative was not 139 
wholly supportive thefollowing trade-offs were described: (1) There was a view that the CDF 140 
was great, but since it only applied to England, and not Wales or Scotland, it was unfair.  (2) 141 
Although the CDF benefited some patients, it also distorted NHS spending and was limited to 142 
helping only a small group of patients.  Possible side effects from the new drugs were only 143 
mentioned in one story in the Financial Times and one in The Guardian.  144 
The cancer drugs and cancer types most often mentioned 145 
The cancer drugs that featured in the newspaper stories were sometimes referred to by their 146 
brand names, and sometimes by their "scientific" names.  Although there were 216 CDF 147 
stories that mentioned specific drugs, the stories were dominated by three systemic therapies, 148 
namely bevacizumab (34 mentions, 15% of all drugs cited), trastuzumab emtasine (33 149 
mentions, 15%) and abiraterone (19 mentions, 9%), see Table 3.  The national audit office 150 
found in its review of CDF-related prescribing that both bevacizumab and abiraterone were 151 
the most commonly prescribed drugs in the CDF in 2013/2014 and 2014/2015 accounting for 152 
19% and 11% of all prescriptions respectively.8  153 
A particular concern relates to the prescribing of bevacizumab.  It was approved for up to 154 
nine indications in the CDF for a variety of tumour types including colorectal, breast, 155 
ovarian, and cervical cancers. A recent analysis found that none of these indications would 156 
have met European Society for Medical Oncology (ESMO) clinical thresholds for meaningful 157 
benefit, and only one indication would meet American Society of Clinical Oncology (ASCO) 158 
criteria.3   159 
In addition, coverage of affected cancer sites did not reflect the most commonly occurring 160 
cancers (incidence) nor those causing the greatest burden, measured in DALYs5.  Figure 3 161 
compares the numbers of mentions of individual cancer sites with the burden of disease in the 162 
UK in 2010 relative to all cancers.  Breast, prostate and colorectal cancer received 163 
significantly greater media coverage than other cancer sites, and in particular, lung cancer.  164 
This is in keeping with breast cancer's greater proportional coverage among all cancer stories: 165 
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it has the most research stories on the BBC and in European newspapers.9,10  Lung cancer, by 166 
contrast, is the leading cause of cancer mortality and disease burden5, but was only mentioned 167 
four times.  168 
DISCUSSION 169 
Our analysis has shown that there was substantial newspaper media support for the CDF, 170 
with our "influence" measure, based on the product of number of articles published and 171 
newspaper circulation, showing three times as much in favour as against.  There is a potential 172 
concern therefore about the influence of media reporting on both demand for, and subsequent 173 
access to the drug through the CDF, although a causal link cannot be proved.   174 
In light of the return of the CDF to the NICE cost-effectiveness umbrella from July 2016, it is 175 
important to reflect on the potential influence of reporting on the execution of the public 176 
policy that led to the CDF.  Media reports did not scrutinise the discrepancy between those 177 
drugs available on the CDF and those diseases with the greatest health burden, the toxicities 178 
of the medicines, nor the opportunity cost of the CDF for other cancer treatments.  Reportage 179 
in some of the most influential newspapers also failed to appraise why some cancer 180 
medicines were funded and others were not in the context of a publicly-funded health system 181 
and public preferences for care in incurable disease.  Access at any cost was a clear totem 182 
around which the pro-CDF media based its coverage.  The views of experts who pointed out 183 
the intrinsic unfairness of the CDF or the lack of efficacy of, and unpleasant side effects 184 
from, many of the drugs seem to have counted for little against the human interest stories of 185 
individual patients.  This is in keeping with evidence from an analysis of American media 186 
coverage of cancer which found that adverse events from cancer treatment were rarely 187 
discussed.8 188 
In many respects the extensive coverage of the CDF closely mirrors a major media 189 
preoccupation with cancer.  Although cancer is responsible for only 21% of DALYs in the 190 
UK, there are many more newspaper stories about research on cancer than about the other 191 
main causes of the UK disease burden, cardiovascular disease (including stroke) and mental 192 
disorders.5 11  Furthermore, the focus on cancer medicines is also notable.  The preponderance 193 
of stories on chemotherapy9, compared with surgery and radiotherapy, has probably 194 
contributed to a strong public perception that the best way to help cancer patients and 195 
improve outcomes is to allow them access to new (and expensive) medicines, whose 196 
performance is often hyped and gives rise to unreasonable expectations.112-151-14  The reason 197 
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for the pre-eminence of chemotherapy in cancer journalism is not clear but is likely to be 198 
related to the volume of press releases by both public and private sectors on the outputs of the 199 
global cancer research endeavour, which is disproportionally focused on fundamental cancer 200 
biology, new medicines and biomarkers.16,17 201 
In an era of ‘alternative facts’ it is imperative that health journalists maintain their credibility 202 
by being critical of the "next big thing" or “game changer” and that the research funders and 203 
institutions assist them in their work.  In the face of the escalating costs of the CDF and its 204 
failure to demonstrate measurable improvements in life expectancy or quality of life for the 205 
patients who were treated, it is important to consider whether unrepresentative media 206 
coverage contributed to the longevity of the CDF and the policy mis-direction that occurred.  207 
In addition to highlighting editorial policies in the print media, this study also draws attention 208 
to the failure of many public organisations, including charitable research funders in the UK, 209 
to publicise the shortcomings of the CDF.  This also must be considered in the context that 210 
there is no evidence that ring-fencing drug-only spending for cancer will improve outcomes 211 
for cancer patients over and above greater investment in the whole cancer management 212 
pathway (screening, diagnostics, radiotherapy, surgery and palliative care). 213 
Our study was limited to the reportage in nine national newspapers, and did not cover other 214 
sources of public information such as broadcasts and social media. The exclusion of 215 
newspapers from the other UK territories was justifiable because the CDF operated only in 216 
England.  It is also important to stress that we are not able to prove causality between media 217 
reporting and the longevity of the CDF.  In future, it would be desirable to complement this 218 
study with a qualitative analysis of how the media affected the policy-makers and physicians 219 
who were principally involved.  It would also be worthwhile to interview some of the leading 220 
journalists in order to discover the frames and drivers that they experienced for their 221 
reportage. 222 
In summary, our analysis demonstrates that the media coverage around the NHS Cancer 223 
Drugs Fund, was largely positive, and unrepresentative in comparison with the lack of overall 224 
benefits to patients and society of the Cancer Drugs Fund, which has since undergone a 225 
substantial overhaul.  In addition, many of the articles espoused the virtues of particular drugs 226 
such as bevacizumab, which failed to deliver improvement in survival or quality of life for 227 
several tumour types according to the original trial evidence.  It is possible that the skewed 228 
media coverage influenced demand and subsequent access for particular drugs through the 229 
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fund, and therefore brings into question the fairness from a public policy perspective of the 230 
NHS Cancer Drugs Fund.  However, it is important to point out that a number of senior 231 
correspondents, commentators and media outlets (e.g. The Guardian) did attempt to redress 232 
the balance.  But compared with the positive reporting and wide distribution of the other UK 233 
national newspapers, they were lone voices in the wilderness.  234 
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Tables 305 
Table 1.  Amount of influence of individual newspapers in their stories about the Cancer 306 
Drugs Fund, based on product of circulation in 2014, number of stories and mean length in 307 
words. DML = Daily Mail; SUN = The Sun; TEL = Daily Telegraph; MIR = Daily Mirror; 308 
DEX = Daily Express; TIM = The Times; IND = The Independent (and i); GDN = The 309 
Guardian; FIT = Financial Times 310 
 Stories Mean words Total words Circulation, k Influence Percent 
DML 82 596 48887 1780 145960 46.3 
SUN 29 379 10989 2210 41990 13.3 
TEL 57 476 27106 550 31350 9.9 
MIR 49 526 25766 990 28710 9.1 
DEX 56 422 23637 500 24500 7.8 
TIM 19 465 8831 380 21280 6.7 
IND 29 619 17939 370 10730 3.4 
GDN 28 798 22343 210 5880 1.9 
FIT 22 638 14026 230 5060 1.6 
Total 371   199523 7220 315460 100.0 
 311 
  312 
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Table 2.  Qualitative codes for CDF stories 313 
Code Significance of the newspaper story Number of stories 
GEO the CDF should have a wider geographical coverage (Wales, 
Scotland) 
88 
MON the CDF is good, but would benefit from more money 60 
GOO the CDF is good generally 29 
PEO the CDF is good and is helping people, including named 
individuals 
23 
DRU the CDF is good, but should cover more drugs 10 
AVA the CDF is good generally but in a context of attacking the NHS: 
e.g  this drug should be available generally, not just via the 
special fund 
9 
OTH the CDF is good, but should also cover other cancer treatments 2 
NEU does not say CDF is good or bad (balanced/neutral) 84 
NHS the CDF is bad because it takes money from the rest of the NHS 59 
NIC the CDF is bad because it undercuts the evidence-based NICE 
recommendations 
9 
LOB the CDF is bad because it is the result of lobbying by drug 
companies and/or patient groups 
8 
SID the CDF is bad because the drugs are ineffective and have nasty 
side-effects 
2 
 314 
  315 
 13 
Table 3.  Individual cancer drugs mentioned in the newspaper stories, with numbers of 316 
mentions. 317 
 318 
Trade name Scientific name N   Trade name Scientific name N 
Avastin bevacizumab 34   Jevtana cabazitaxel 2 
Kadcyla trastuzumab emtansine 33   Soliris eculizumab 2 
Zytiga abiraterone 19   Sprycel dasatinib 2 
Xtandi enzalutamide 11   Tarceva erlotinib 2 
Erbitux cetuximab 10   Xalkori crizotinib 2 
Yervoy ipilimumab 9   Alimta pemetrexed 1 
Zelboraf vemurafenib 8   Arzerra ofatumumab 1 
Halaven eribulin 7   Campath alemtuzumab 1 
Perjeta pertuzumab 7   Gleevec imatinib 1 
Tyverb lapatinib 7   Glucophage metformin 1 
Lynparza olaparib 6   Ibrance palbociclib 1 
Nexavar sorafenib 6   Imnovid pomalidomide 1 
Sutent sunitinib malate 6   Keytruda pembrolizumab 1 
Abraxane protein-bound paclitaxel 4   Mabthera rituximab 1 
Opdivo nivolumab 4   Sertex serratiopeptidase 1 
Vedotin brentuximab 4   Sovaldi sofosbuvir 1 
Gleevec imatinib 3   Stivarga regorafenib 1 
Revlimid lenalidomide 3   Synribo omacetaxine 1 
Afinitor everolimus 2   Tasigna nilotinib 1 
Bosulif bosutinib 2   Taxol paclitaxel 1 
Herceptin trastuzumab 2   Taxotere docetaxel 1 
Inlyta axitinib 2   Vectibix panitumumab 1 
 319 
  320 
 14 
Figure legends 321 
Figure 1.  Numbers of stories about the Cancer Drugs Fund in nine national UK newspapers, 322 
2010-15.  For codes, see Table 1. (Sunday Times stories excluded as it is not a daily 323 
newspaper). 324 
Figure 2.  The tone of the cancer drugs fund stories in the 10 newspapers, 2010-15.  For 325 
newspaper codes see Table 1 and for story character codes see Table 2. Green solid/shaded: 326 
positive reporting of CDF; White: neutral or balanced; Red-Pink solid/shaded: negative 327 
reporting of CDF. 328 
Figure 3.  Comparison of numbers of mentions of cancer sites in CDF stories, 2010-15, with 329 
relative disease burden in the UK from cancers at these sites, 2010.  330 
 331 
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